Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Cardinal Health Inc    CAH

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Cardinal Health to Buy Medical-Supplies Provider AssuraMed for $2.07 Billion

02/14/2013 | 08:08am US/Eastern
   By Melodie Warner 
 

Cardinal Health Inc. (>> Cardinal Health, Inc.) agreed to acquire closely held medical-supplies provider AssuraMed for $2.07 billion as the drug wholesaler looks to diversify its offerings.

AssuraMed currently serves more than one million patients nationally with more than 30,000 products. The company bought Invacare Corp.'s (>> Invacare Corporation) domestic medical supplies business for $150 million last month. Including that business, Cardinal Heath said AssuraMed had 2012 revenue of $1 billion.

After the transaction is complete, Cardinal Health will supply ostomy, diabetes, insulin therapy, urological, wound care and incontinence products to the home-healthcare market.

"This is a platform opportunity for Cardinal Health products and services which will be increasingly important as the delivery of care migrates to more cost-effective settings," said Chairman and Chief Executive George Barrett.

Cardinal Health expects AssuraMed to add two cents to three cents a share to its fiscal 2013 adjusted earnings, assuming the deal closes by early April.

The company also estimates its will boost fiscal 2014 adjusted earnings by at least 18 cents a share.

Cardinal has previously disclosed the loss of its contract with pharmacy-benefits manager Express Scripts Holding Co. (>> Express Scripts Holding Co) to rival AmerisourceBergen Corp. (>> AmerisourceBergen Corp.). Two of Cardinal's huge drug-distribution customers, Walgreen Co. (>> Walgreen Company) and CVS Caremark Corp. (>> CVS Caremark Corporation), have contracts set to end this summer.

The company earlier this month reported its fiscal second-quarter earnings rose 16% as improved margins helped to offset weaker revenue at its pharmaceutical division, which was caused partly by generic-drug introductions.

Shares closed Wednesday at $45.44 and were inactive premarket. The stock has risen 8% over the past year.

Write to Melodie Warner at melodie.warner@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

React to this article
Latest news on CARDINAL HEALTH INC
02/04 CARDINAL HEALTH : Expert Shares How Hospitals Can Prepare For 340B Drug Pricing ..
02/04 CARDINAL HEALTH : Expert Shares How Hospitals Can Prepare For 340B Drug Pricing ..
02/02 ATHENA SAN DIEGO PRESENTS : Men Who Champion Women, A Signature Series Event
02/02 CARDINAL HEALTH : Management's Discussion and Analysis of Financial Condition an..
02/02 CARDINAL HEALTH : Board of Directors Approves Quarterly Dividend
02/02 CARDINAL HEALTH : TIDI Products Appoints New Chief Operations Officer and New Ch..
02/01DJCARDINAL HEALTH : Revenue Rises 23% - Update
02/01DJCardinal Health Revenue Rises 23%
02/01DJCARDINAL HEALTH : Revenue Rises 23%
02/01 CARDINAL HEALTH : tops Street 2Q forecasts
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials